← All trials
NCT04260802
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ocellaris Pharma, Inc.Lead sponsor
- Ocellaris Pharma, Inc.Study director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Carcinoma, Hepatocellular
- Neoplasms
- Ovarian Neoplasms
- Sarcoma
- Stomach Neoplasms
- Carcinoma, Merkel Cell
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.